Effects of interactions of antibacterial drugs with each other and with 6-mercaptopurine on in vitro growth of Mycobacterium avium subspecies paratuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Krishnan, Manju Y ^a   Manning, Elizabeth J B ^a   Collins, Michael T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antibiotics; Crohn's disease; Drug combination; FIC; Immunomodulator; Paratuberculosis; Susceptibility

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; MERCAPTOPURINE; RIFABUTIN; RIFAMPICIN; IMMUNOLOGIC FACTOR;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; DRUG EFFECT; DRUG INTERACTION; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PARATUBERCULOSIS;

6-MERCAPTOPURINE; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; PARATUBERCULOSIS;

EID: 73949148083     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp339     Document Type: Article

References (32)

1. Mitchison DA. Combined antimicrobial treatment in tuberculosis and in non tuberculosis infections. In: Brumfitt W, Curcio L, Silvestri L, eds. Combined Antibacterial Therapy. The Hague: M. Nijhoff Publishers, 1979; 45-58.
2. Chacon O, Bermudez LE, Barletta RG. Johne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu Rev Microbiol 2004; 58: 329-63.
3. Behr MA, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr Opin Gastroenterol 2008; 24: 17-21.
4. Pineton de Chambrun G, Colombel JF, Poulain D et al. Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008; 24: 440-7.
5. Abubakar I, Myhill D, Aliyu SH et al. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflamm Bowel Dis 2008; 14: 401-10.
6. Feller M, Huwiler K, Stephan R et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007;7:607-13.
7. Gui GP, Thomas PR, Tizard ML et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 1997; 39: 393-400.
8. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterol 1995; 108: A826.
9. Hermon-Taylor J, Barnes N, Clarke C et al. Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. BMJ 1998; 316: 449-53.
10. Shafran I, Kugler L, El-Zaatari FA et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002; 34: 22-8.
11. Borody TJ, Bilkey S, Wettstein AR et al. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig Liver Dis 2007; 39: 438-44.
12. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 2000; 14: 801-6.
13. Goodgame RW, Kimball K, Akram S et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1861-6.
14. Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-9.
15. Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob Agents Chemother 1992; 36: 2843-6.
16. Krishnan MY, Manning EJB, Collins MT. Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother 2009; 64: 310-6.
17. Bermudez LE, Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. Curr Pharm Des 2004; 10: 3221-8.
18. Carter G, Young LS, Bermudez LE. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. Antimicrob Agents Chemother 2004; 48: 4907-10.
19. Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007; 20: 198-203.
20. Hultén K, Almashhrawi A, El-Zaatari FA et al. Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria. Dig Dis Sci 2000; 45: 445-56.
21. Akobeng AK. Crohn's disease: current treatment options. Arch Dis Child 2008; 93: 787-92.
22. Wright S, Sanders DS, Lobo AJ et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-8.
23. Greenstein RJ, Su L, Haroutunian V et al. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS ONE 2007; 2: e161.
24. Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother 2008; 52: 418-26.
25. Collins MT, Lisby G, Moser C et al. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol 2000; 38: 4373-81.
26. Heifets LB, Iseman MD, Lindholm-Levy PJ. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis 1988; 137: 711-5.
27. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
28. Chan GL, Erdmann GR, Gruber SA et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-63.
29. Van Os EC, Zins BJ, Sandborn WJ et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996; 39: 63-8.
30. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-57.
31. Piersimoni C, Tortoli E, Mascellino MT et al. Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. J Antimicrob Chemother 1995; 36: 497-502.
32. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35: 462-70.